Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-722-2 | CAS number: 13943-58-3
According to the REACH Guidance IR CSA R.7c, an assessment on the toxicokinetic properties of the substace has been performed, resulting in low absorption via de oral and dermal route, while via the inhalation route no significant inhalable fraction is present due to the high particle size.
In general, a compound needs to be dissolved before it can be taken up from the gastro-intestinal tract after oral administration. Therefore, the good water solubility favors the uptake from the gastro-intestinal tract. However, the presence of ionisable groups and the moderate high molecular weight are indicative for impaired absorption, as ionized substances do not easily pass the gastro-intestinal wall. It is therefore unlikely that potassium ferrocyanide will show a high systemic exposure after oral administration. Based on the available physical/chemical properties of potassium ferrocyanide, for risk assessment purposes the oral absorption is set at 10%. The results of the toxicity studies do not provide reasons to deviate from this proposed oral absorption factor.
Excretion of the target's analogue, sodium ferrocyanide, occurs mainly via urine through glomerular filtration ands is assumed too for potassium ferrocyanide based on the similar physcial and chemical properties. Bioaccumulation is not expected for this substance, as during metabolism cyanide will be transformed to thiocyanide, which has a plasma half-life of less than 1 hour.
In humans, particles with aerodynamic diameters below 100 µm have the potential to be inhaled. Based on the high particle size, physical state and vapour pressure of potassium ferrocyanide, the potential for inhalation is negligble. According to the criteria given in the REACH Guidance, 10% dermal absorption will be considered in case MW>500 and log Pow <-1 or >4, otherwise 100% dermal absorption should be used. As the physical/chemical properties of potassium ferrocyanide do not meet the criteria for limited dermal absorption, for risk assessment purposes 100% dermal absorption needs to be considered. It is, however, generally accepted that dermal absorption is lower compared to oral absorption. The 100% dermal absorption derived from the physical/chemical properties of the substance should therefore be considered as unrealistic worst case assumption. For risk assessment purposes a lower dermal absorption value of 10% is considered more appropriate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again